We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · September 01, 2022

Neoadjuvant Endocrine Therapy for Strongly HR-Positive and HER2-Negative Early Breast Cancer

Breast Cancer Research and Treatment

 

Additional Info

Disclosure statements are available on the authors' profiles:

Breast Cancer Research and Treatment
Neoadjuvant endocrine therapy for strongly hormone receptor-positive and HER2-negative early breast cancer: results of a prospective multi-center study
Breast Cancer Res Treat 2022 Aug 02;[EPub Ahead of Print], X Wang, Z Fan, X Wang, Y He, Y Liu, X Wang, B Zhang, Z Jiang, T Wang, Z Yu, F Wang, Y Liu, Y Li, J Zhang, B Luo, H Jiang, T Wang, Y Xie, J Li, T Ouyang

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading